Yurdanur Erdogan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yurdanur Erdogan has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Berna Akıncı Özyürek
Department of Pulmonology, University of Health Sciences, Ankara Atatürk Sanatorium Training and Research Hospital, Ankara 06300, Türkiye
10 shared publications - Derya Yenibertiz
Department of Pulmonology, University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Türkiye
5 shared publications - Nilgün Yılmaz Demirci
Department of Chest Diseases, Gazi University Faculty of Medicine, Ankara, Turkey
3 shared publications - Ülkü Yılmaz
Department of Chest Diseases, Ankara Atatürk Sanatorium Training and Research Hospital, 06290 Ankara, Türkiye
3 shared publications - Aslıhan Gürün Kaya
Department of Chest Diseases, Ankara University Faculty of Medicine, Ankara, Türkiye
2 shared publications - Aydın Yılmaz
Department of Pulmonology, University of Health Sciences, Ankara Atatürk Sanatorium Education and Research Hospital, 06010 Ankara, Türkiye
2 shared publications
Latest Publications
- Open Access
- 26 April 2025
- Published by Kirikkale Universitesi Tip Fakultesi Dergisi in Kırıkkale Üniversitesi Tıp Fakültesi Dergisi
- Vol. 27 (1) , 22-28
THE SIGNIFICANCE OF QUANTITATIVE DATA FROM PET/CT IN THE COURSE OF SARCOIDOSIS AND THEIR ASSOCIATION WITH CLINICAL PARAMETERS
Objectives: To examine the potential correlation between the presence of a disease outside the chest and the likelihood of recurrence or need for therapy, as well as to assess the relationship between quantitative measurements obtained from 18F-FDG PET/CT scans and clinical and laboratory markers associated with sarcoidosis. Material and Methods: 18F-FDG PET/CT images of 78 patients diagnosed with sarcoidosis were retrospectively examined. The SUV max value of the lesions with the highest uptake in the thoracic and extrathoracic regions of the disease was determined. Clinical and laboratory parameters, and SUV max values of the lesions were compared. The relationship between the detection of an extrathoracic disease and the need for treatment, and the development of recurrence was also investigated. Results: No significant correlation was found between patients with thoracic and extrathoracic disease regarding SUVmax and clinical and laboratory results (p>0.05). A significant correlation was detected between the SUVmax value of mediastinal lymph nodes and the presence of extrathoracic disease (p
- 26 April 2025
- Published by Kirikkale Universitesi Tip Fakultesi Dergisi in Kırıkkale Üniversitesi Tıp Fakültesi Dergisi
- Vol. 27 (1) , 22-28
Open AccessTHE SIGNIFICANCE OF QUANTITATIVE DATA FROM PET/CT IN THE COURSE OF SARCOIDOSIS AND THEIR ASSOCIATION WITH CLINICAL PARAMETERS
Objectives: To examine the potential correlation between the presence of a disease outside the chest and the likelihood of recurrence or need for therapy, as well as to assess the relationship between quantitative measurements obtained from 18F-FDG PET/CT scans and clinical and laboratory markers associated with sarcoidosis. Material and Methods: 18F-FDG PET/CT images of 78 patients diagnosed with sarcoidosis were retrospectively examined. The SUV max value of the lesions with the highest uptake in the thoracic and extrathoracic regions of the disease was determined. Clinical and laboratory parameters, and SUV max values of the lesions were compared. The relationship between the detection of an extrathoracic disease and the need for treatment, and the development of recurrence was also investigated. Results: No significant correlation was found between patients with thoracic and extrathoracic disease regarding SUVmax and clinical and laboratory results (p>0.05). A significant correlation was detected between the SUVmax value of mediastinal lymph nodes and the presence of extrathoracic disease (p
- 1 January 2025
- Published by Bayrakol Medical Publishing in Eurasian Clinical and Analytical Medicine
- Vol. 13 (01) , 1-5
Prognostic value of c-Kit and vascular endothelial growth factor immunoreactivity for limited-stage small-cell lung cancer
- 1 January 2025
- Published by Bayrakol Medical Publishing in Eurasian Clinical and Analytical Medicine
- Vol. 13 (01) , 1-5
Prognostic value of c-Kit and vascular endothelial growth factor immunoreactivity for limited-stage small-cell lung cancer
- Open Access
- 10 September 2024
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 72 (3) , 197-207
Association of mean platelet volume (MPV), MPV/PLATELET (PLT) ratio, and lymphocyte/ monocyte ratio (LMR) as poor prognostic factor in EGFR-mutant lung adenocarcinoma treated with EGFR tyrosine kinase inhibitor
Platelets (PLT) and host systemic inflammatory response (SIR) are known to be effective in the aggregation of cancer cells and the formation of metastasis. There are studies pointing out to the prognostic efficacy of lymphocyte-monocyte ratio (LMR) showing SIR activation and mean platelet volume (MPV) values indicating platelet activation in various cancer types. We predict that easy-to-access hemogram parameters such as MPV, MPV/PLT, and LMR can be guiding in the clinical follow-up period of patients with epidermal growth factor receptor (EGFR) positive mutation and who received EGFR, tyrosine kinase inhibitor (TKI) in the first-line treatment in predicting the progression of the disease, predicting the survival time of the patients, and evaluating the response to treatment. The study is retrospective and included patients with stage III and stage IV pulmonary adenocarcinoma with positive EGFR mutations and for whom TKI was used in the first-line treatment between January 2011 and January 2021. MPV, MPV/PLT, and LMR values of the patients were calculated before treatment. Age, sex, comorbidity, smoking history, TNM stage, metastasis localizations, EGFR mutation types, TKI treatments used in first-line treatment, and MPV, MPV/PLT, and LMR values at the 1st month of treatment were recorded. With Kaplan-Meier, six-month, one-year, three-year, and five-year survival rates, average life expectancy, and 95% confidence intervals for these periods were calculated. Variables that may affect progression and overall survival (OS) were determined by performing univariate and multivariate Cox regression analysis. One hundred and two patients were included in the study. The mean age of the patients was 64.30 ± 12.6 years. Eighty-four patients were in stage IV at the time of diagnosis. The expected mean progression-free survival (PFS) period of the cases was found to be 13.3 months. The mean life expectancy of the cases was found to be 35.1 months. Web-based Cutoff Finder algorithm written in the R program (http://molpath.charite.de/cutoff) was used to determine the ideal cut points for MPV, MPV/PLT, and LMR. The cut-off values were found to be 7.55 fL for MPV, 0.251 for MPV/PLT, and 2.615 for LMR, respectively. In univariate Cox regression analysis, LMR level lower than 2.615 increased the rate of progression 1.747 times (95% confidence interval: 1.129-2.705) and the death rate 2.056 times (95% confidence interval: 1.217-3.475) (p= 0.012, p= 0.007). The mean PFS LMR cut-off value was 10.3 months, and 15.3 months, and mean OS durations were 25.1 months and 40.8 months for the groups with low and high cut-off values respectively (p= 0.011, p= 0.006 log-rank test). According to the results of multivariate Cox regression analysis, MPV/PLT< 0.251, smoking, presence of pleural and adrenal metastases, and gefitinib treatment were independent factors in determining PFS. The independent factors determining OS in multivariate Cox regression analysis were being male, platelet increase, MPV> 7.55, gefitinib treatment, and smoking. MPV, MPV/PLT, and LMR are potential biomarkers that can be used for the clinical follow-up of lung ADC patients receiving EGFR-TKI treatment.
- 10 September 2024
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 72 (3) , 197-207
Open AccessAssociation of mean platelet volume (MPV), MPV/PLATELET (PLT) ratio, and lymphocyte/ monocyte ratio (LMR) as poor prognostic factor in EGFR-mutant lung adenocarcinoma treated with EGFR tyrosine kinase inhibitor
Platelets (PLT) and host systemic inflammatory response (SIR) are known to be effective in the aggregation of cancer cells and the formation of metastasis. There are studies pointing out to the prognostic efficacy of lymphocyte-monocyte ratio (LMR) showing SIR activation and mean platelet volume (MPV) values indicating platelet activation in various cancer types. We predict that easy-to-access hemogram parameters such as MPV, MPV/PLT, and LMR can be guiding in the clinical follow-up period of patients with epidermal growth factor receptor (EGFR) positive mutation and who received EGFR, tyrosine kinase inhibitor (TKI) in the first-line treatment in predicting the progression of the disease, predicting the survival time of the patients, and evaluating the response to treatment. The study is retrospective and included patients with stage III and stage IV pulmonary adenocarcinoma with positive EGFR mutations and for whom TKI was used in the first-line treatment between January 2011 and January 2021. MPV, MPV/PLT, and LMR values of the patients were calculated before treatment. Age, sex, comorbidity, smoking history, TNM stage, metastasis localizations, EGFR mutation types, TKI treatments used in first-line treatment, and MPV, MPV/PLT, and LMR values at the 1st month of treatment were recorded. With Kaplan-Meier, six-month, one-year, three-year, and five-year survival rates, average life expectancy, and 95% confidence intervals for these periods were calculated. Variables that may affect progression and overall survival (OS) were determined by performing univariate and multivariate Cox regression analysis. One hundred and two patients were included in the study. The mean age of the patients was 64.30 ± 12.6 years. Eighty-four patients were in stage IV at the time of diagnosis. The expected mean progression-free survival (PFS) period of the cases was found to be 13.3 months. The mean life expectancy of the cases was found to be 35.1 months. Web-based Cutoff Finder algorithm written in the R program (http://molpath.charite.de/cutoff) was used to determine the ideal cut points for MPV, MPV/PLT, and LMR. The cut-off values were found to be 7.55 fL for MPV, 0.251 for MPV/PLT, and 2.615 for LMR, respectively. In univariate Cox regression analysis, LMR level lower than 2.615 increased the rate of progression 1.747 times (95% confidence interval: 1.129-2.705) and the death rate 2.056 times (95% confidence interval: 1.217-3.475) (p= 0.012, p= 0.007). The mean PFS LMR cut-off value was 10.3 months, and 15.3 months, and mean OS durations were 25.1 months and 40.8 months for the groups with low and high cut-off values respectively (p= 0.011, p= 0.006 log-rank test). According to the results of multivariate Cox regression analysis, MPV/PLT< 0.251, smoking, presence of pleural and adrenal metastases, and gefitinib treatment were independent factors in determining PFS. The independent factors determining OS in multivariate Cox regression analysis were being male, platelet increase, MPV> 7.55, gefitinib treatment, and smoking. MPV, MPV/PLT, and LMR are potential biomarkers that can be used for the clinical follow-up of lung ADC patients receiving EGFR-TKI treatment.
- 26 July 2021
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 75 (10) , e14635
The evaluation of lung involvement and functional capacities in patients diagnosed with primary Sjogren’s syndrome
Introductıon Sjögren syndrome is a chronic, systemic, inflammatory disease characterized with lymphocytic infiltration of the exocrine glands, frequently manifested by dryness in the region affected. Although the most common extraglandular involvement in SS is pulmonary involvement. Early diagnosis and treatment is considered to be important. It was aimed to evaluate the frequency of early lung involvement, high resolution computed tomography (HRCT) findings and data of pulmonary function test (PFT) in SS in this study. Materıal-Method Thirty five patients diagnosed with SS and referred by the Department of Rheumatology to determine potential lung involvement to the 8th chest diseases outpatient clinic of our hospital between September 2015 and december 2018 were included in this study. Respiratory signs, demographic features, length of disease and treatment regimens, PFT, data of 6-minute walk test (MWT) and findings of HRCT of the patients were retrospectively obtained from hospital information system and patient files. Results The mean age of the patients was 54.4 ± 9.2. The majority of the patients were women (94.3%). When the HRCT findings were evaluated, 28 (80%) patients had CT findings, while 7 (20%) patients had no CT findings. The most common HRCT findings found in patients were peribronchial thickening (48.6 %), ground glass appearance (28.6%) and prominence in interstitial scars. Conclusion We think that the evaluation of HRCT and PFTs in patients diagnosed with SS for assessing early pulmonary involvement will be guiding in terms of follow-up and treatment.
- 26 July 2021
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 75 (10) , e14635
The evaluation of lung involvement and functional capacities in patients diagnosed with primary Sjogren’s syndrome
Introductıon Sjögren syndrome is a chronic, systemic, inflammatory disease characterized with lymphocytic infiltration of the exocrine glands, frequently manifested by dryness in the region affected. Although the most common extraglandular involvement in SS is pulmonary involvement. Early diagnosis and treatment is considered to be important. It was aimed to evaluate the frequency of early lung involvement, high resolution computed tomography (HRCT) findings and data of pulmonary function test (PFT) in SS in this study. Materıal-Method Thirty five patients diagnosed with SS and referred by the Department of Rheumatology to determine potential lung involvement to the 8th chest diseases outpatient clinic of our hospital between September 2015 and december 2018 were included in this study. Respiratory signs, demographic features, length of disease and treatment regimens, PFT, data of 6-minute walk test (MWT) and findings of HRCT of the patients were retrospectively obtained from hospital information system and patient files. Results The mean age of the patients was 54.4 ± 9.2. The majority of the patients were women (94.3%). When the HRCT findings were evaluated, 28 (80%) patients had CT findings, while 7 (20%) patients had no CT findings. The most common HRCT findings found in patients were peribronchial thickening (48.6 %), ground glass appearance (28.6%) and prominence in interstitial scars. Conclusion We think that the evaluation of HRCT and PFTs in patients diagnosed with SS for assessing early pulmonary involvement will be guiding in terms of follow-up and treatment.
- 31 December 2020
- Published by Ordu University in MIDDLE BLACK SEA JOURNAL OF HEALTH SCIENCE
- Vol. 6 (3) , 333-339
Evaluation of Anxiety and Depression in Idiopathic Pulmonary Fibrosis
Objective: Depression and anxiety are the comorbid diseases of Idiopathic Pulmonary Fibrosis (IPF) and these diseases are more frequently in patients with serious progressive types of IPF. The aim of this study was to use the Hospital Anxiety and Depression Scale (HADS) to evaluate the levels of depression and anxiety in IPF patients.Methods: A total of 27 patients were included to the study. Demographic characteristics, pulmonary function tests, GAP indexes (gender, age, and physiology), 6-minute walk test (MWT) values were recorded from the patient files. To measure the levels of anxiety and depression in patients with IPF, the validated Turkish version of the HADS, including 14 questions, was used.Results: Anxiety was determined in 33.3% of the patients and depression was detected in 37% of the patients. The patients’ avearage anxiety score was 5.5 and the mean depression score was 6.2. Desaturation in patients with anxiety was significantly higher (p<0.05) and was found to be higher in patients with depression (p<0.05). DLCO levels were detected to be lower in patients with depression (p <0.05).Conclusion: The quality of life of patients diagnosed with IPF can be improved by psychiatric assessment and adequate supportive care, including antidepressant medication and psychological therapy.
- 31 December 2020
- Published by Ordu University in MIDDLE BLACK SEA JOURNAL OF HEALTH SCIENCE
- Vol. 6 (3) , 333-339
Evaluation of Anxiety and Depression in Idiopathic Pulmonary Fibrosis
Objective: Depression and anxiety are the comorbid diseases of Idiopathic Pulmonary Fibrosis (IPF) and these diseases are more frequently in patients with serious progressive types of IPF. The aim of this study was to use the Hospital Anxiety and Depression Scale (HADS) to evaluate the levels of depression and anxiety in IPF patients.Methods: A total of 27 patients were included to the study. Demographic characteristics, pulmonary function tests, GAP indexes (gender, age, and physiology), 6-minute walk test (MWT) values were recorded from the patient files. To measure the levels of anxiety and depression in patients with IPF, the validated Turkish version of the HADS, including 14 questions, was used.Results: Anxiety was determined in 33.3% of the patients and depression was detected in 37% of the patients. The patients’ avearage anxiety score was 5.5 and the mean depression score was 6.2. Desaturation in patients with anxiety was significantly higher (p<0.05) and was found to be higher in patients with depression (p<0.05). DLCO levels were detected to be lower in patients with depression (p <0.05).Conclusion: The quality of life of patients diagnosed with IPF can be improved by psychiatric assessment and adequate supportive care, including antidepressant medication and psychological therapy.
- Open Access
- 22 October 2020
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 3 (4) , 421-426
Küçük hücreli akciğer kanseri tanısı konulan hastalarda C-reaktif protein/albumin oranının prognoz tayinindeki yeri ile PET-BT’deki primer kitlenin çapı ve suvmax değeri ile ilişkisi
Tr en Giriş-amaç: Küçük hücreli akciğer kanseri (KHAK) tüm akciğer kanser türlerinin %15’ ini oluşturur. Çalışmamızda KHAK tanısı konulan hastalarda retrospektif olarak ilk tanı anında bakılan C-reaktif protein/ albümin (CAR)’ın prognoz tayinindeki yeri ile primer kitlenin PET-BT’ deki çapı ve SUV max değeri ile ilişkisinin değerlendirilmesini amaçladık. Materyal-metod: Çalışmamızda hastanemiz 8. kliniğinde Ocak 2008- Aralık 2015 tarihleri arasında KHAK tanısı konulan 70 hasta dahil edildi. Hastalara ait bilgiler hasta dosyaları ve hastane bilgi sisteminden retrospektif olarak elde edildi. İlk tanı anında bakılan hemogram, biyokimya değerleri, PET-BT’ deki primer kitlenin çapı, SUVmax değerleri, kanser evresi, sağkalım süreleri kayıt edildi. NLR: nötrofil/lenfosit, CAR: C-reaktif protein/albümin oranları hesaplandı. Bulgular: Hastaların ortalama yaşı 57,6±7,5 olarak hesaplandı. 59 hasta (%84,3) exitus iken, 11 hasta (%15,7) halen sağ idi. Hastaların median izlem süresi 13,7 (8,1-30,1) ay idi. CAR <0,3 olanlarda ortalama yaşam süresi 21 ay iken, ≥ 0,3 olanlar da 10 ay olarak bulundu (p:0,007). LDH<187 olanlarda median ömür 23 ay, ≥187 olanlarda ise 10 ay olarak bulunmuştur (p: 0 ,048). NLR <3 olanlarda median yaşam süresi 19 ay, ≥ 3 olanlarda 10 ay olarak bulunmuştur. Sonuç istatistiksel olarak anlamlılık sınırına yakın olarak değerlendirilmiştir (p:0,073). Sonuç: Erkek cinsiyet, hastalığın evresi ve primer kitlenin SUVmax değerindeki artış, artmış CAR, artmış NLR ve artmış LDH KHAK’lı hastalarda kötü prognoz kriteleri olarak saptadık. CAR, NLR ve LDH düzeylerinin tanı anındaki mortaliteyi öngörmede kullanılabileceklerini düşünmekteyiz. Introduction: In our study, we aimed to evaluate retrospectively the role of C-reactive protein/ albumin rate (CAR) in determining prognosis of patients diagnosed with SCLC and the relationship with the diameter and SUV max value of primer mass in Positron emission tomography/ computed tomography (PET-CT). Materials and Methods: A total of 70 patients diagnosed with SCLC between January 2008 and December 2015 in this study. Informations of patients were recorded. Results: The mean age of the patients was 57.6±7.5. While 59 patients (84.3%) were dead, 11 patients (15.7%) were still alive. The median follow-up time of the patients was 13. 7 (8.1-30.1) month. The mean life span was found to be 21 month in patients with CAR <0.3, and it was found to be 10 month in patients with CAR≥ 0.3 (p=0.007). Median lifespan was 23 month in patients with LDH <187 and it was 10 month in patients with ≥187 (p= 0.048). Median life span was found as 19 month in patients with NLR <3 and it was found to be 10 month in patients with NLR ≥ 3. The result was evaluated as close to statistical significance (p= 0.073). Conclusion: We detected that male gender, the stage of disease, the increase of SUVmax value of primary mass and increased CAR, NLR and LDH levels were found to be poor prognostic criterias in SCLC patients. We consider that CAR, NLR and LDH levels can be used for forecasting of mortality at the begining of the diagnoses of SCLC
- 22 October 2020
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 3 (4) , 421-426
Open AccessKüçük hücreli akciğer kanseri tanısı konulan hastalarda C-reaktif protein/albumin oranının prognoz tayinindeki yeri ile PET-BT’deki primer kitlenin çapı ve suvmax değeri ile ilişkisi
Tr en Giriş-amaç: Küçük hücreli akciğer kanseri (KHAK) tüm akciğer kanser türlerinin %15’ ini oluşturur. Çalışmamızda KHAK tanısı konulan hastalarda retrospektif olarak ilk tanı anında bakılan C-reaktif protein/ albümin (CAR)’ın prognoz tayinindeki yeri ile primer kitlenin PET-BT’ deki çapı ve SUV max değeri ile ilişkisinin değerlendirilmesini amaçladık. Materyal-metod: Çalışmamızda hastanemiz 8. kliniğinde Ocak 2008- Aralık 2015 tarihleri arasında KHAK tanısı konulan 70 hasta dahil edildi. Hastalara ait bilgiler hasta dosyaları ve hastane bilgi sisteminden retrospektif olarak elde edildi. İlk tanı anında bakılan hemogram, biyokimya değerleri, PET-BT’ deki primer kitlenin çapı, SUVmax değerleri, kanser evresi, sağkalım süreleri kayıt edildi. NLR: nötrofil/lenfosit, CAR: C-reaktif protein/albümin oranları hesaplandı. Bulgular: Hastaların ortalama yaşı 57,6±7,5 olarak hesaplandı. 59 hasta (%84,3) exitus iken, 11 hasta (%15,7) halen sağ idi. Hastaların median izlem süresi 13,7 (8,1-30,1) ay idi. CAR <0,3 olanlarda ortalama yaşam süresi 21 ay iken, ≥ 0,3 olanlar da 10 ay olarak bulundu (p:0,007). LDH<187 olanlarda median ömür 23 ay, ≥187 olanlarda ise 10 ay olarak bulunmuştur (p: 0 ,048). NLR <3 olanlarda median yaşam süresi 19 ay, ≥ 3 olanlarda 10 ay olarak bulunmuştur. Sonuç istatistiksel olarak anlamlılık sınırına yakın olarak değerlendirilmiştir (p:0,073). Sonuç: Erkek cinsiyet, hastalığın evresi ve primer kitlenin SUVmax değerindeki artış, artmış CAR, artmış NLR ve artmış LDH KHAK’lı hastalarda kötü prognoz kriteleri olarak saptadık. CAR, NLR ve LDH düzeylerinin tanı anındaki mortaliteyi öngörmede kullanılabileceklerini düşünmekteyiz. Introduction: In our study, we aimed to evaluate retrospectively the role of C-reactive protein/ albumin rate (CAR) in determining prognosis of patients diagnosed with SCLC and the relationship with the diameter and SUV max value of primer mass in Positron emission tomography/ computed tomography (PET-CT). Materials and Methods: A total of 70 patients diagnosed with SCLC between January 2008 and December 2015 in this study. Informations of patients were recorded. Results: The mean age of the patients was 57.6±7.5. While 59 patients (84.3%) were dead, 11 patients (15.7%) were still alive. The median follow-up time of the patients was 13. 7 (8.1-30.1) month. The mean life span was found to be 21 month in patients with CAR <0.3, and it was found to be 10 month in patients with CAR≥ 0.3 (p=0.007). Median lifespan was 23 month in patients with LDH <187 and it was 10 month in patients with ≥187 (p= 0.048). Median life span was found as 19 month in patients with NLR <3 and it was found to be 10 month in patients with NLR ≥ 3. The result was evaluated as close to statistical significance (p= 0.073). Conclusion: We detected that male gender, the stage of disease, the increase of SUVmax value of primary mass and increased CAR, NLR and LDH levels were found to be poor prognostic criterias in SCLC patients. We consider that CAR, NLR and LDH levels can be used for forecasting of mortality at the begining of the diagnoses of SCLC
- 6 July 2020
- Published by Galenos Yayinevi in Turkish Thoracic Journal
- Vol. 21 (4) , 255-260
Evaluation of Thiol/Disulfide Homeostasis in Lung Cancer
Lung cancer,oxidative stress,thiol/disulfide homeostasis,mortality
- 6 July 2020
- Published by Galenos Yayinevi in Turkish Thoracic Journal
- Vol. 21 (4) , 255-260
Evaluation of Thiol/Disulfide Homeostasis in Lung Cancer
Lung cancer,oxidative stress,thiol/disulfide homeostasis,mortality
- Open Access
- 18 June 2020
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 3 (3) , 317-323
The prognostic role of gender, age and physiology index and C-reactive protein/albumin ratio in idiopathic pulmonary fibrosis
Aim: We aimed to compare the gender, age, and physiology index and C-reactive protein/albumin ratio in order to evaluate the prognosis, clinical course and survival of patients with idiopathic pulmonary fibrosis.Material and Method: Forty-seven patients with idiopathic pulmonary fibrosis diagnosed by radiologically or pathologically in the 8th clinic of our hospital between January 2013 and December 2018 included to the study. Demographic characteristics, pulmonary function tests, 6-minute walk test values, echocardiography results, life span, additional diseases, treatment information, laboratory results of patients, gender, age and physiology indexes and initial C-reactive protein/albumin ratio of the patients were recorded from the patient files. Results: According to gender, age and physiology index there were 25 (53.2%) patients in stage I, 11 (23.4%) patients in stage II, and 11 (23.4%) patients in stage III. The patients were divided into 2 groups according to their life conditions. The rate of respiratory failure, the mean pulmonary arterial pressure and gender, age, and physiology stage were significantly higher (p grup 0.05) in the exitus group. The 6- minute walk test was significantly lower in the exitus group (p<0.05). C-reactive protein/albumin ratio results were similar in both groups and there were no significant differences according to other parameters in both groups too. There was no significant difference between the C-reactive protein/albumin ratio values of the patients in each of the three gender, age, and physiology stages.Conclusion: Gender, age, and physiology stage is easy and useful but C-reactive protein/albumin ratio isn’t convenient to predict the prognosis of idiopathic pulmonary fibrosis. The elevation of pulmonary arterial pressure, low 6 minute walk test and presence of respiratory failure are poor prognostic factors in idiopathic pulmonary fibrosis.
- 18 June 2020
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 3 (3) , 317-323
Open AccessThe prognostic role of gender, age and physiology index and C-reactive protein/albumin ratio in idiopathic pulmonary fibrosis
Aim: We aimed to compare the gender, age, and physiology index and C-reactive protein/albumin ratio in order to evaluate the prognosis, clinical course and survival of patients with idiopathic pulmonary fibrosis.Material and Method: Forty-seven patients with idiopathic pulmonary fibrosis diagnosed by radiologically or pathologically in the 8th clinic of our hospital between January 2013 and December 2018 included to the study. Demographic characteristics, pulmonary function tests, 6-minute walk test values, echocardiography results, life span, additional diseases, treatment information, laboratory results of patients, gender, age and physiology indexes and initial C-reactive protein/albumin ratio of the patients were recorded from the patient files. Results: According to gender, age and physiology index there were 25 (53.2%) patients in stage I, 11 (23.4%) patients in stage II, and 11 (23.4%) patients in stage III. The patients were divided into 2 groups according to their life conditions. The rate of respiratory failure, the mean pulmonary arterial pressure and gender, age, and physiology stage were significantly higher (p grup 0.05) in the exitus group. The 6- minute walk test was significantly lower in the exitus group (p<0.05). C-reactive protein/albumin ratio results were similar in both groups and there were no significant differences according to other parameters in both groups too. There was no significant difference between the C-reactive protein/albumin ratio values of the patients in each of the three gender, age, and physiology stages.Conclusion: Gender, age, and physiology stage is easy and useful but C-reactive protein/albumin ratio isn’t convenient to predict the prognosis of idiopathic pulmonary fibrosis. The elevation of pulmonary arterial pressure, low 6 minute walk test and presence of respiratory failure are poor prognostic factors in idiopathic pulmonary fibrosis.
- 14 March 2020
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 14 (8) , 689-694
Is Onodera’s prognostic nutritional index (OPNI) a prognostic factor in small cell lung cancer (SCLC)?
Introduction: We aimed to evaluate the prognostic value of Onodera’s prognostic nutritional index (OPNI) in patients with Small‐cell lung cancer (SCLC).Materials and methods: This study retrospectively examined 109 patients diagnosed with SCLC between January 2008 and October 2018 in our hospital. Patients were divided into two groups according to the median of OPNI values.Results: A significant difference was observed between the groups in terms of neutrophil percentage, lymphocyte count, lymphocyte percentage, C‐reactive protein (CRP), albumin, lactat dehidrogenase (LDH) and neutrophil to lymphocyte ratio (NLR) (P < 0.05). LDH, CRP, neutrophil percentage and NLR (P = 0.008, P < 0.001, P = 0.001, P < 0.001, respectively) were significantly higher and albumin, lymphocyte count and lymphocyte percentage (P < 0.001, P < 0.001, P = 0.001, respectively) were significantly lower in the low OPNI group. Survival analyses have shown that mortality rates and lifespan are similar in the two groups.Conclusion: The OPNI may be a helpful tool for determining the prognosis in SCLC.
- 14 March 2020
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 14 (8) , 689-694
Is Onodera’s prognostic nutritional index (OPNI) a prognostic factor in small cell lung cancer (SCLC)?
Introduction: We aimed to evaluate the prognostic value of Onodera’s prognostic nutritional index (OPNI) in patients with Small‐cell lung cancer (SCLC).Materials and methods: This study retrospectively examined 109 patients diagnosed with SCLC between January 2008 and October 2018 in our hospital. Patients were divided into two groups according to the median of OPNI values.Results: A significant difference was observed between the groups in terms of neutrophil percentage, lymphocyte count, lymphocyte percentage, C‐reactive protein (CRP), albumin, lactat dehidrogenase (LDH) and neutrophil to lymphocyte ratio (NLR) (P < 0.05). LDH, CRP, neutrophil percentage and NLR (P = 0.008, P < 0.001, P = 0.001, P < 0.001, respectively) were significantly higher and albumin, lymphocyte count and lymphocyte percentage (P < 0.001, P < 0.001, P = 0.001, respectively) were significantly lower in the low OPNI group. Survival analyses have shown that mortality rates and lifespan are similar in the two groups.Conclusion: The OPNI may be a helpful tool for determining the prognosis in SCLC.
- 4 January 2020
- Published by Wolters Kluwer Health in Journal of Occupational and Environmental Medicine
- Vol. 63 (3) , 238-243
Effect of Asbestos Exposure on the Frequency of EGFR Mutations and ALK/ROS1 Rearrangements in Patients With Lung Adenocarcinoma
Objective: The aim of this study is to investigate the effect of asbestos exposure on cancer-driver mutations. Methods: Between January 2014 – September 2018, EGFR, ALK, and ROS1 alterations, demographic characteristics, asbestos exposure, and asbestos-related radiological findings of 1,904 patients with lung adenocarcinoma were recorded. Results: The frequencies of EGFR mutations, ALK and ROS1 rearrangements were 14.5%, 3.7% and 0.9%, respectively. The rates of EGFR mutations and ALK rearrangements were more frequent in asbestos exposed non-smokers (48,7% and 9%, respectively). EGFR mutation rate was correlated to female gender and not-smoking, ALK rearrangement rate was correlated to younger age, not-smoking and a history of asbestos exposure. Conclusions: The higher rate of ALK rearrangements in asbestos-exposed lung adenocarcinoma cases shows that asbestos exposure may most likely cause genetic alterations that drive pulmonary adenocarcinogenesis.
- 4 January 2020
- Published by Wolters Kluwer Health in Journal of Occupational and Environmental Medicine
- Vol. 63 (3) , 238-243
Effect of Asbestos Exposure on the Frequency of EGFR Mutations and ALK/ROS1 Rearrangements in Patients With Lung Adenocarcinoma
Objective: The aim of this study is to investigate the effect of asbestos exposure on cancer-driver mutations. Methods: Between January 2014 – September 2018, EGFR, ALK, and ROS1 alterations, demographic characteristics, asbestos exposure, and asbestos-related radiological findings of 1,904 patients with lung adenocarcinoma were recorded. Results: The frequencies of EGFR mutations, ALK and ROS1 rearrangements were 14.5%, 3.7% and 0.9%, respectively. The rates of EGFR mutations and ALK rearrangements were more frequent in asbestos exposed non-smokers (48,7% and 9%, respectively). EGFR mutation rate was correlated to female gender and not-smoking, ALK rearrangement rate was correlated to younger age, not-smoking and a history of asbestos exposure. Conclusions: The higher rate of ALK rearrangements in asbestos-exposed lung adenocarcinoma cases shows that asbestos exposure may most likely cause genetic alterations that drive pulmonary adenocarcinogenesis.